Harrow, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Nashville, TN. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $272 million and a loss of $5 million (its filed statements).
Product businessPharmaceutical PreparationsNashville, TNfilings since 20069 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.8 out of ten, 9 of 9 metrics filed: past 5.7 out of ten, present 6.2 out of ten, future 5.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 4.5 out of ten. 3 warning events since 2017; the latest 2025-09-19. 45th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 7.5 out of ten. +33.6% a year over 9 filed years; profitable in 2 of 9. 75th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.6 out of ten. Share count grew 10.2% a year. 0% of cash flow returned. Insiders: 1 sales, 4 purchases. 36th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 6.3 out of ten. ROE -10%: lost 10¢ per shareholder dollar. Leverage 87%: owes 87¢ per asset dollar. 63rd percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 7.5 out of ten. top 25% of 314 in its family; net margin -1.9%. 75th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.2 out of ten. bottom 42% of 315 in its family for leadership; chief executive since 2012. 42nd percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.9 out of ten. bottom 39% of 272 in its family for room to expand. 39th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 7.1 out of ten. top 29% of 307 in its family for growth drivers. 71st percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.6 out of ten. top 44% of 234 in its family for expectations against reality. 56th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-02 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-10 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-10 (on EDGAR). Newest filing: Form 8-K, 2026-10-05. Filings on record since 2006. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Branded 72%, Imprimis Rx 28%. As tagged in its annual report (Form 10-K, filed 2026-03-02).
Who runs it
Baum, Mark L (CHIEF EXECUTIVE OFFICER); Mullery, Francis William Jr (CEO, ImprimisRx); Boll, Andrew R. (PRESIDENT AND CFO); Shojaei, Amir (CHIEF SCIENTIFIC OFFICER); Sullivan, Patrick William (CHIEF COMMERCIAL OFFICER); Pollard, Randall E. (CHIEF ACCOUNTING OFFICER); Graves, Adrienne L (director); Silvernail, Lauren P (director); Sternberg, Perry J. (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.